Vertex Pharmaceuticals in T1D Licensing Pact With TreeFrog Therapeutics
Vertex Pharmaceuticals Inc VRTX
News
-
VERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO OPTIMIZE PRODUCTION OF VERTEX'S CELL THERAPIES FOR TYPE 1 DIABETES
Vertex's stock climbs as non-opioid pain treatment advances
Vertex Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic Pain
Vera Therapeutics Shares Rise 9.9% After Alpine Acquisition
Alpine Immune Sciences Shares Rally After Vertex Agrees to Acquire Co.
Vertex Pharmaceuticals to Acquire Alpine Immune Sciences for $4.9 Billion — Update
Vertex Pharmaceuticals to acquire Alpine Immune Sciences for $4.9 billion
Vertex Pharmaceuticals to Acquire Alpine Immune Sciences for $4.9 Billion
Vertex Enters Into Agreement to Acquire Alpine Immune Sciences
Vertex Enters Into Agreement to Acquire Alpine Immune Sciences
Vertex to Announce First Quarter 2024 Financial Results on May 6
Vertex Advances Inaxaplin (VX-147) into Phase 3 Portion of Adaptive Phase 2/3 Clinical Trial for the Treatment of APOL1-Mediated Kidney Disease
Thinking about trading options or stock in Tesla, Energy Transfer, Paramount Global, Vertex Pharmaceuticals, or Broadcom ?
Vertex Gets FDA OK to Study VX-407 in Genetic Kidney Disease
Vertex Announces FDA Clearance of Investigational New Drug Application for VX-407 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
This biotech ETF sees 'breakout' while U.S. small-cap technology stocks lag
Vertex Pharmaceuticals Cystic Fibrosis Drug Gets Positive Opinion in EU For Treatment in Infants
Vertex to Participate in Upcoming Investor Conferences
European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia